RPS19 and Diamond-Blackfan anemia: To investigate the efficacy of the therapeutic LVs to correct the phenotype of HSCs from RPS19-mutated DBA, BM CD34+ cells from these patients were transduced with either therapeutic vector or with a control LV (EGFP LV) (Table 1).